Implementing Evidence-Driven Individualized Treatment Plans within Morquio A Syndrome

http://academiccme.com/wp-content/uploads/2015/05/Screen-Shot-2015-05-09-at-6.39.40-PM.png

Course Information

Therapautic Area: Genetics and Genomics
Format(s): Webcast
Credit(s): N/A
Activity Dates: April 27, 2015 - April 26, 2016

 

This course is still available as a learning tool but has expired for CME credit.

Program Overview

This CME symposium on the management of patients with Morquio A syndrome will provide updated information and guidelines concerning the early and accurate diagnosis as well as an earlier intervention to improve patient outcomes. Recent advances in the science of enzyme replacement therapies have presented opportunities for pharmacological interventions that improve quality of life. Clinicians will be updated on the clinical trial data and practical solutions for applying newer therapeutics to daily practice. Strategies to manage cardiopulmonary comorbidities and recommendations for the ideal clinical care model will wrap up this informative and up-to-date review of Morquio A syndrome.

Target Audience

Medical geneticists, anesthesiology, orthopedic, pulmonary, and cardiac specialists, and other healthcare professionals who manage patients within Morquio A Syndrome.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the diagnostic characteristics and updated treatment guidelines for MPS IVA/Morquio A syndrome
  2. Examine pharmacologic therapeutic options for MPS IVA/MorquioA syndrome, and associated efficacy and safety data, including enzyme replacement therapeutics (ERTs)
  3. Analyze available surgical options in the treatment of MPS IVA/Morquio A, as well as methods to minimize safety risks in the case of surgical complications
  4. Develop and implement individualized treatment plans into the care of patients with MPS IVA, appropriately integrating pharmacologic and surgical options

Registration



This activity has been supported by an independent educational grant from BioMarin Pharmaceuticals Inc.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME EOCME-AcademicCME-Co-provided_061214